CN116570676A - Application of seaweed Yu Hu Tang in preparing medicament for treating or relieving silicosis - Google Patents
Application of seaweed Yu Hu Tang in preparing medicament for treating or relieving silicosis Download PDFInfo
- Publication number
- CN116570676A CN116570676A CN202310350867.9A CN202310350867A CN116570676A CN 116570676 A CN116570676 A CN 116570676A CN 202310350867 A CN202310350867 A CN 202310350867A CN 116570676 A CN116570676 A CN 116570676A
- Authority
- CN
- China
- Prior art keywords
- parts
- silicosis
- seaweed
- jade
- soup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001474374 Blennius Species 0.000 title claims abstract description 76
- 201000010001 Silicosis Diseases 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 235000014347 soups Nutrition 0.000 claims abstract description 45
- 239000010977 jade Substances 0.000 claims abstract description 42
- 230000004761 fibrosis Effects 0.000 claims abstract description 23
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 230000004054 inflammatory process Effects 0.000 claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 claims abstract description 18
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 17
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 16
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 16
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 16
- 239000000428 dust Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 48
- 210000004072 lung Anatomy 0.000 claims description 44
- 239000000377 silicon dioxide Substances 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 20
- 241000213006 Angelica dahurica Species 0.000 claims description 11
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 11
- 241000675108 Citrus tangerina Species 0.000 claims description 11
- 241001522129 Pinellia Species 0.000 claims description 11
- 241000605372 Fritillaria Species 0.000 claims description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 241000112528 Ligusticum striatum Species 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- 235000011477 liquorice Nutrition 0.000 claims description 10
- 235000012239 silicon dioxide Nutrition 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 230000037361 pathway Effects 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 230000028709 inflammatory response Effects 0.000 claims description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 241000212322 Levisticum officinale Species 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000001645 levisticum officinale Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 208000004852 Lung Injury Diseases 0.000 description 7
- 206010069363 Traumatic lung injury Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 231100000515 lung injury Toxicity 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010056342 Pulmonary mass Diseases 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000028571 Occupational disease Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medicines, relates to a novel medicinal application of seaweed jade pot soup, and in particular relates to an application of seaweed jade pot soup in preparing medicines for treating or relieving silicosis. The technical scheme for solving the problems is to provide an effective alternative scheme for treating or relieving the inflammatory reaction and the fibrosis of silicosis induced by production dust by utilizing modern traditional Chinese medicine, and the technical scheme for solving the problems is to provide the application of the seaweed jade kettle decoction in preparing the medicines for treating or relieving the inflammatory reaction and the fibrosis process of silicosis. The seaweed jade kettle soup can effectively relieve productive dust-induced silicosis inflammatory reaction and pulmonary fibrosis, can obviously reduce inflammatory factors generated at silicosis sites, inhibit TGF-beta/Smad channels, and obstruct fibrosis progress, and has good application prospect.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of seaweed jade pot soup in preparing medicines for treating or relieving silicosis.
Background
As one of the most widespread and oldest occupational diseases worldwide, silicosis is most widely distributed in the industries of ore mining, metal processing, stone construction and the like, and the most important cause of pathogenicity is the deposition of nondegradable free silica dust particles in the lungs. As the disease progresses, severe inflammatory reactions and fibrosis occur in the lungs of the afflicted population, which can be progressive and fatal, with irreversible damage to lung function. The pathogenesis of silicosis (i.e., silicosis) is not clear, and no effective treatment means exists at present, so that the disease deterioration and the life quality improvement can be only realized by avoiding contact with dust, alveolar lavage, inhibiting the inflammatory process, relieving the pulmonary fibrosis and other various comprehensive management strategies. In addition, the existing method for treating silicosis has the problems of poor treatment effect, high cost, large side effect of medicines and the like. And most silicosis patients belong to middle and low income groups, and high medical cost is difficult to support, so that the search for a high-efficiency and low-cost silicosis treatment scheme is urgent.
Modern traditional Chinese medicine has a certain curative effect and advantages in silicosis treatment and effective delay of patient disease progress, and at present, research has shown that traditional Chinese medicine extracts are proved to be clinically effective, such as tetrandrine. The inventor of the invention based on clinical observation and ancient book examination, the seaweed jade kettle soup has the effects of eliminating stasis and reducing inflammation, and the inventor expects to use the seaweed jade kettle soup to have an effect on silicosis treatment. Studies show that the seaweed jade kettle soup can participate in immunoregulation, relieve autoimmune thyroiditis, and has therapeutic effects on diseases such as hypothyroidism, thyromegaly, hyperplasia of mammary glands, vocal nodule and the like.
The silicosis diagnosis firstly carries out professional medical history investigation of contacting free silicon dioxide particles, further completes analysis and examination of chest films before and after high kilovolt X-ray, pulmonary function and arterial blood gas, and combines clinical manifestation and X-ray chest film for diagnosis. In Western medicine clinical treatment, silicosis has no cure method, and only aims at stage conditions, and the medicines are applied to the patients. Lung nodules, which are often confused with silicosis, are solid or sub-solid shadows of the lung, which are represented by imaging as circles or quasi-circles with diameters less than or equal to 3cm and have increased density, and belong to a multisystem non-cheesed granulomatous disease with unknown etiology, which often invade the lung portals, mediastinal lymph nodes and lung tissues, and are a completely different diagnosis and treatment principle from silicosis. Based on the dialectical treatment of traditional Chinese medicine, the dialectical treatment of silicosis comprises 6 types of symptoms such as non-dispersing of lung qi, phlegm heat accumulated in lung, yin deficiency and lung heat, chest yang blockage, lung spleen phlegm dampness, lung and kidney deficiency, and the like, the patients are mainly concentrated on men, and the patients are regulated by activating blood circulation to remove blood stasis, dispersing lung qi and regulating qi so as to achieve the aim of improving the life quality of the patients, but the patients are difficult to cure; the lung nodule is caused by qi and blood dampness and phlegm stagnation in the lung, and is mostly caused by qi deficiency and mass groups, wherein women are more, the treatment is carried out by taking strengthening body resistance to eliminate pathogenic factors as the core, and a doctor can regulate the lung from qi, blood and water to treat the nodule, so that the aim of complete cure is fulfilled.
Aiming at fibrosis and inflammatory reaction occurring in silicosis, the invention does not have a report on how seaweed Yu Hui Tang is used for relieving or treating diseases such as lung injury or pulmonary fibrosis caused by productive dust at present.
Disclosure of Invention
The invention solves the technical problem of providing a secondary medical application of the seaweed jade kettle soup, and provides an effective alternative scheme for treating or relieving silicosis, in particular to producing dust-induced silicosis.
The technical scheme for solving the technical problems is as follows: provides the application of the seaweed jade kettle soup in preparing the medicines for treating or relieving silicosis.
In particular, the invention provides an application of seaweed jade pot soup in preparing a medicament for treating or relieving inflammatory reaction and fibrosis progress of silicosis.
The technical scheme is as follows:
wherein the silicosis is induced by production dust; in particular, silicosis injury or silicosis fibrosis is induced by production dust. The productive dust referred to in the present invention refers to silicon dust with a free silica content of more than 10%.
Further, silicosis injury induced by production dust is a silicosis inflammatory reaction.
Still further, the inflammatory response of silicosis is characterized by an elevated content of inflammatory factors IL-1 beta, IL-6, TGF-beta in the lung tissue.
The seaweed jade kettle soup can achieve the effect of reducing the content of inflammatory factors (IL-1 beta, IL-6 and TGF-beta) in lung tissues.
Still further, silicosis fibrosis induced by the production dust is characterized by the activation of the TGF- β/Smad pathway, a classical fibrotic pathway, the activation of which is intimately associated with collagen deposition and EMT processes, inducing or accelerating the fibrotic process.
The seaweed jade kettle soup can inhibit the abnormal expression of TGF-beta/Smad pathway related proteins in the lung tissue, and can relieve the degree of pulmonary fibrosis in the silicosis tissue.
Furthermore, the fibrosis process of silicosis is an early stage fibrosis process.
The seaweed and kelp in the seaweed jade kettle soup adopted by the invention can resolve phlegm and soften hardness, dissipate stagnation and eliminate gall, and are key medicines for treating gall, and are all monarch medicines. The green tangerine peel and the dried orange peel can promote qi circulation and resolve depression, so that qi is smooth and phlegm is eliminated; chinese angelica and ligusticum wallichii activate blood and regulate nutrient. The four medicines are combined, and the Chinese medicinal composition has the effects of promoting blood circulation, regulating qi and blood, and helping to dissipate stagnation and remove gall, and is taken as ministerial medicine. With the assistance of pinellia tuber and fritillary bulb for resolving phlegm and eliminating stagnation, and combining with monarch drugs, the effect of resolving phlegm and eliminating stagnation and eliminating gall is remarkable; fructus forsythiae clears heat and eliminates stagnation, and radix angelicae pubescentis are dispersed to dredge collaterals. Glycyrrhrizae radix and Sargassum are used as adjuvants by taking their opposite phases to excite the potency of the drugs and harmonizing the drugs. The composition of the components in the following weight ratio is adopted:
25 parts of seaweed, 25 parts of kelp, 15 parts of fritillaria, 15 parts of pinellia ternate, 20 parts of green tangerine peel, 20 parts of dried orange peel, 20 parts of Chinese angelica, 20 parts of ligusticum wallichii, 15 parts of fructus forsythiae, 15 parts of radix angelicae pubescentis and 6 parts of liquorice.
On the basis of the mature proved recipe, the weight ratio can be properly expanded into a range value, and the seaweed jade kettle soup can be prepared from the following components in parts by weight:
25-35 parts of seaweed, 25-35 parts of kelp, 10-20 parts of fritillaria, 10-20 parts of pinellia ternate, 15-25 parts of green tangerine peel, 15-25 parts of dried orange peel, 20-25 parts of Chinese angelica, 20-25 parts of ligusticum wallichii, 10-20 parts of fructus forsythiae, 5-15 parts of radix angelicae pubescentis and 4-8 parts of liquorice.
When the seaweed jade kettle soup is used for treating or relieving silicosis, pharmaceutically acceptable auxiliary materials or auxiliary components are added into the components with the weight ratio range or the optimal value, so that the seaweed jade kettle soup is prepared into an oral preparation.
The oral preparation comprises a solid preparation, a liquid preparation or a suspension preparation.
Further, the solid preparation comprises capsules, tablets, pills, powder or granules.
Further, the liquid preparation comprises emulsion, solution, suspension, syrup or tincture.
Specifically, the preparation method of the seaweed jade kettle soup adopted by the invention comprises the following steps:
A. weighing the following raw materials in parts by weight: 25-35 parts of seaweed, 25-35 parts of kelp, 10-20 parts of fritillaria, 10-20 parts of pinellia ternate, 15-25 parts of green tangerine peel, 15-25 parts of dried orange peel, 20-25 parts of Chinese angelica, 20-25 parts of ligusticum wallichii, 10-20 parts of fructus forsythiae, 5-15 parts of radix angelicae pubescentis and 4-8 parts of liquorice;
B. soaking in water, and decocting under the following conditions: adding water 4-6 times, decocting for 1-2 times, each for 20-40 min, and collecting decoction.
Preferably, the step A is characterized in that the raw material medicines are weighed according to the following components in parts by weight: 25 parts of seaweed, 25 parts of kelp, 15 parts of fritillaria, 15 parts of pinellia ternate, 20 parts of green tangerine peel, 20 parts of dried orange peel, 20 parts of Chinese angelica, 20 parts of ligusticum wallichii, 15 parts of fructus forsythiae, 15 parts of radix angelicae pubescentis and 6 parts of liquorice.
Preferably, in the step B, the decoction is carried out for 5-15 minutes by strong fire and then 15-25 minutes by slow fire; more preferably, the decoction is carried out by decocting with strong fire for 10 min and then decocting with slow fire for 20 min.
Preferably, the decocting conditions in step B are: adding water 5 times, decocting for 1 time and 30 minutes each time, and collecting decoction.
Preferably, the soaking time in the step B is 5-15 minutes; it is further preferred that the soaking time in step B is 10 minutes.
The invention creatively provides the effect of the seaweed jade kettle soup in preparing the medicines for treating or relieving inflammatory reaction and fibrosis progress of silicosis. The seaweed jade kettle soup can effectively relieve lung injury or diseases induced by production dust, such as pneumonitis reaction and pulmonary fibrosis, inhibit immune reaction caused by silicon dioxide, block TGF-beta/Smad pathway activation, and relieve the pulmonary fibrosis degree at a silicosis focus.
Drawings
FIG. 1 graph of body weight gain of mice 14 days after intervention of seaweed Yu Hui Tang in silicosis model mice.
FIG. 2A staining pattern of lung tissue HE of mice (5X, 20X) 14 days after intervention of seaweed Yu Hui Tang in silicosis model mice.
FIG. 3 Masson staining pattern of lung tissue of mice 14 days after intervention of seaweed Yu pot soup in silicosis model mice (5X, 20X).
FIG. 4 graph of body weight gain of mice 35 days after intervention of seaweed Yu Hui Tang in silicosis model mice.
FIG. 5A staining pattern of lung tissue HE of mice 35 days after intervention of seaweed Yu Hui Tang in silicosis model mice (5X, 20X).
FIG. 6 Masson staining pattern of lung tissue of mice 35 days after intervention of seaweed Yu pot soup in silicosis model mice (5X, 20X).
FIG. 7 shows the expression level of TGF-beta, smad2, smad3, P-Smad2 and P-Smad3 proteins in lung tissue of mice 35 days after intervention of seaweed Yuhu decoction in silicosis model mice.
FIG. 8 histogram of IL-1. Beta. Inflammatory factor content in lung tissue of mice 14 days and 35 days after intervention of seaweed Yu Hui Tang in silicosis model mice.
FIG. 9 histogram of IL-6 inflammatory factor content in lung tissue of mice 14 days and 35 days after intervention of seaweed Yu Hui Tang in silicosis model mice.
FIG. 10 histogram of TGF-beta inflammatory factor content in lung tissue of mice 14 days and 35 days after intervention of seaweed Yu Hui Tang in silicosis model mice.
Detailed Description
As used herein, "treatment" refers to therapeutic or prophylactic measures that can be achieved to alleviate or mitigate a disease, control or prevent an undesired physiological condition, disorder or disease, or to achieve a beneficial or desired clinical result. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; a reduction in the extent of a condition, disorder, or disease; stabilization (i.e., not worsening) of the condition, disorder, or disease state; delay or slowing of the occurrence of a condition, disorder, or disease progression; improvement or alleviation (whether partial or complete) of a condition, disorder, or disease state, whether detectable or undetectable; or an improvement or amelioration of a condition, disorder, or disease. Treatment involves eliciting a clinically significant response without undue levels of side effects.
In the present invention, the "inflammatory reaction" refers to a reaction that induces immune cell aggregation and inflammatory factor release in the lung after inhalation and deposition from exogenous free silica particles. Early silicosis involves the recognition and phagocytosis of silica by macrophages, but the inability to digest causes autophagy or apoptosis of macrophages, and releases a large amount of inflammatory factors that attract other immune cells to aggregate, inducing inflammation. The inflammation in the lung nodules is mostly caused by immunological disorder, which is different from silicosis.
Through a great deal of creative work, the invention provides the application of the seaweed jade kettle soup in preparing the medicines for treating or relieving silicosis. In the preparation of medicines for treating or relieving silicosis, the administration route of the seaweed jade kettle soup is mainly an oral mode; the weight ratio of the raw materials is as follows: 25 parts of seaweed, 25 parts of kelp, 15 parts of fritillaria, 15 parts of pinellia ternate, 20 parts of green tangerine peel, 20 parts of dried orange peel, 20 parts of Chinese angelica, 20 parts of ligusticum wallichii, 15 parts of fructus forsythiae, 15 parts of radix angelicae pubescentis and 6 parts of liquorice. On the basis of the mature proved recipe, the weight ratio can be properly expanded, and the seaweed jade kettle soup still has the corresponding or equivalent effects of treating or relieving early inflammatory reaction of silicosis or pulmonary fibrosis, and the weight ratio range of the seaweed jade kettle soup raw material medicine is as follows: 25-35 parts of seaweed, 25-35 parts of kelp, 10-20 parts of fritillaria, 10-20 parts of pinellia ternate, 15-25 parts of green tangerine peel, 15-25 parts of dried orange peel, 20-25 parts of Chinese angelica, 20-25 parts of ligusticum wallichii, 10-20 parts of fructus forsythiae, 5-15 parts of radix angelicae pubescentis and 4-8 parts of liquorice.
When the seaweed jade kettle soup is used for preparing the medicine for treating or relieving silicosis, the raw materials of the components with the weight proportion range or the optimal value of the seaweed jade kettle soup can be taken, the seaweed jade kettle soup is prepared into an oral decoction according to a traditional Chinese medicine conventional preparation method, and pharmaceutically acceptable auxiliary materials or auxiliary components can be added to prepare other preparations common in the field.
In the invention, strong fire is a Chinese medicine noun. The fire power is large and rapid when decocting the medicine. The decoction should be performed with strong fire followed by slow fire. Some herbs which are not suitable for long-term decoction are only used with strong fire, such as Di Xue Yao and Xiang Yao.
In the invention, slow fire is also a Chinese medicine noun. The fire power is small and slow when the medicine is decocted. After the herbs are boiled, they are decocted with slow fire and slow fire. For the recipe of nourishing and tonifying herbs with thick taste, it should be decocted with slow fire for a long time. In contrast to a strong fire.
The pharmaceutically acceptable auxiliary component has certain physiological activity, but the addition of the component does not change the dominant position of the pharmaceutical composition in the disease treatment process, but only plays auxiliary effects, and the auxiliary effects are only the utilization of the known activity of the component and are auxiliary treatment modes which are conventional in the medical field. If the auxiliary components are used together with the pharmaceutical composition of the present invention, the auxiliary components still fall within the scope of the present invention.
The scheme of the present invention will be explained below with reference to examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Establishment of model of lung injury of mice in embodiment and in vivo animal experiment of intervention of seaweed Yu Hu Tang
1. Silica-induced pulmonary disease modeling
1) Animal species
C57BL/6J, male mouse, 8 weeks old, 23-25g
2) Reagent(s)
Silica (Sigma), 200 ℃,2h dry heat sterilization, dissolved in sterile physiological saline for standby, and mixed into suspension by high-speed vortex before use.
The seaweed jade kettle soup is prepared by adding 1000ml of water according to the following proportion, soaking for 10 minutes, decocting with strong fire (big fire) for 10 minutes, decocting with slow fire (small fire) for 20 minutes, and finally predicting 300-400ml of soup.
Seaweed jade kettle soup ingredient list
3) Method of
And injecting pentobarbital sodium (50-55 mg/kg) into the abdominal cavity according to the body weight to anesthetize the mice, gently pinching toe tips to observe whether obvious reflex reaction exists or not so as to judge whether the anesthesia depth is reached, and carrying out subsequent experiments.
Mice reaching the anesthesia depth were fixed on the console, and the incisors were fixed with surgical wires to fix the heads.
The tongue of the mouse is gently pulled out by forceps, the neck of the mouse is irradiated by a mercury lamp light source, and the mouth of the air tube is found by naked eye observation, so that the point which is suddenly and suddenly breathed by the mouse is found, namely the mouth of the air tube.
The hose of the indwelling needle is inserted into the trachea of a mouse, the mouse is lifted, 80 mu L of evenly mixed silicon dioxide suspension (50 mg/mL) is rapidly injected, the indwelling needle is pulled out, the forceps gently pull the tongue of the mouse, choking cough and choking are avoided, after the mouse breathes steadily, the mouse is put back into the cage, vital signs of the mouse are observed, and the mouse is recovered until the mouse wakes up.
2. Research on alleviation of silica-induced lung diseases by seaweed Yu Hu Tang
1) Grouping and intervention
Control group (control), model group (model), seaweed jade kettle Shang Gao dose group (40 mg/kg, HYD high dose group, HYD-H group), seaweed jade kettle soup low dose group (20 mg/kg, HYD low dose group, HYD-L group) 5-8 animals each. The control group was tracheal instilled with an equal volume of physiological saline.
2) Intervention method
The stomach is irrigated by mouth, seaweed Yuhu decoction is dissolved by normal saline, working solution of 5.5g/mL (calculated by dry medicinal materials) is prepared, when the intervention is performed, the high-dose group is given with stock solution, the low-dose group is irrigated after being diluted in half, and the stomach irrigation amount is determined according to the body weight. Mice were sacrificed 14 days and 35 days after continuous dosing, respectively.
3) Evaluation index
Mouse body weight, mouse blood biochemical index, lung tissue H & E staining and scoring, lung tissue Masson staining and scoring, lung tissue inflammatory factor IL-1 beta, IL-6, TGF-beta content, lung tissue TGF-beta, smad2, smad3, P-Smad2 and P-Smad3 protein expression. The experimental results are shown in figures 1-10 respectively.
Under normal physiological conditions, the weight of animals is increased until stable, and the weight is easy to change when the body is subjected to acute injury or gastrointestinal tract stimulation. As shown in fig. 1, after 14 days of silica induction, the weight of each group of mice showed a stable growth trend, which indicates that acute damage is not caused to the mice in the molding process, and stomach irritation is not caused to the mice by stomach irrigation of the seaweed yu pot soup; as shown in fig. 4, after 35 days of silica induction, the body weight of each group of mice showed a stable growth trend and reached a stable state in the later period, indicating that the long-term stomach infusion of the seaweed yu pot soup did not generate obvious toxic and side effects on the mice.
Silicosis is a progressive disease and can be divided into inflammatory stage, inflammatory and fibrotic coexisting stage, and fibrotic stage. The animal model adopted by the invention is a silicosis model of 2 weeks (14 days) and 5 weeks (35 days), and is in an early stage of silicosis, wherein 2 weeks are in an inflammatory stage, and 5 weeks are in an inflammation and fibrosis coexisting stage.
As shown in fig. 2 and 5, the H & E staining results showed: (1) The control group has complete lung tissue structure, single-layer cells on the alveolar wall, no obvious exudation in the alveolar space, no inflammatory cell infiltration and fibroblast proliferation, and is a normal lung tissue structure. (2) After induction with silica, the mouse alveolar structure was destroyed, the alveolar space was widened, massive lymphocyte infiltration was seen, and aggregation of macrophages, mast cells, fibroblasts occurred, accompanied by tissue vascular proliferation, evident alveolar lesions, alveolar wall thickening, fibroblast proliferation, and diffuse fibrosis of the lung tissue were seen in the lung tissue at day 35. The above manifestations suggest substantial lung injury and fibrosis formation. (3) Compared with the model group, the intervention of the seaweed jade kettle soup (HYD-H group and HYD-L group) can obviously improve the damage of lung tissue results, maintain the integrity of alveoli, relieve inflammatory infiltration, and relieve lung injury induced by silicon dioxide, especially the lung tissue performance of the HYD-H group and the control group.
As shown in fig. 3 and 6, masson staining results showed that: (1) After instillation through the silicon dioxide trachea, obvious collagen deposition exists in the lung clearance of the five-week silicosis model, dense fibrous scar balls appear in the existing partial areas, and immune cell aggregation is carried out on the periphery. (2) The intervention of seaweed jade kettle soup (HYD-H group and HYD-L group) can obviously inhibit the induction effect of silicon dioxide compared with a model group, and the HYD-H group and the HYD-L group have similar lung tissue expression compared with a control group.
Under the stimulation of free silicon dioxide, immune cells can release the fibroblast growth factor TGF-beta, induce the TGF-beta/Smad channel to activate, promote the collagen expression of fibroblasts and epithelial cells, and deepen the fibrosis progress of silicosis. As shown in FIG. 7, under the intervention of seaweed Yu Hui Tang, the expression level of TGF-beta, P-Smad2 and P-Smad3 in lung tissues is reduced, and the pathway is inhibited, so that the fibrosis progress of silicosis is slowed down. Silica induces lung injury, an inflammatory response that can occur early in the injury and persist throughout the course of the disease. As shown in fig. 8-10, after the induction of the silica, the content of inflammatory factors in lung tissues is obviously increased, so that the silica is suggested to induce the lung tissues to generate inflammatory response, and the intervention of the seaweed jade kettle soup can effectively reduce the level of inflammatory factors in the lung tissues caused by the silica, so that the seaweed jade kettle soup is suggested to relieve the inflammatory response induced by the silica. (all values are expressed as mean ± SEM, P <0.05, P <0.01, P <0.001, P <0.0001, each group compared to the model group)
The experimental results show that the seaweed jade kettle soup can inhibit the release of inflammatory factors, alleviate the inflammatory reaction of lung tissues, relieve the process of silicosis fibrosis by blocking TGF-beta/Smad channels, and improve the pneumonic injury and the pulmonary fibrosis induced by silicon dioxide. The seaweed Yu Hu Tang is effective on inflammatory reaction (week 2 and week 5) and early fibrosis (week 5) in silicosis progression. The seaweed jade kettle soup can block the evolution of the seaweed jade kettle soup to severe and irreversible fibrosis, and avoid further worsening of symptoms of patients suffering from silicosis.
In conclusion, the seaweed jade kettle soup can effectively relieve lung injury or diseases induced by production dust, such as pneumonitis reaction and pulmonary fibrosis, inhibit immune reaction caused by silicon dioxide, block TGF-beta/Smad pathway activation, and relieve the degree of pulmonary fibrosis at a silicosis focus, and provides a new choice for clinical practice in terms of relieving and recovering silicosis caused by production dust.
Claims (10)
1. The seaweed Yu Hu Tang is applied to the preparation of medicines for treating or relieving silicosis.
2. The seaweed Yu Hu Tang is used for preparing the medicine for treating or relieving inflammatory reaction and fibrosis progress of silicosis.
3. Use according to claim 1 or 2, characterized in that: the silicosis is silicosis injury or silicosis fibrosis induced by production dust;
preferably, the productive dust is silicon dust with free silicon dioxide content more than 10%.
4. A use according to claim 3, characterized in that: the silicosis injury is silicosis inflammatory reaction.
5. The use according to claim 4, characterized in that: the treatment or alleviation of the inflammatory response of silicosis is the reduction of the content of inflammatory factors IL-1 beta, IL-6, TGF-beta in the lung tissue.
6. A use according to claim 3, characterized in that: treatment or alleviation of silicosis injury and pulmonary fibrosis is the inhibition of abnormal expression of TGF-beta/Smad pathway-associated proteins in lung tissue.
7. A use according to claim 3, characterized in that: the fibrosis process of silicosis is early stage fibrosis process.
8. Use according to any one of claims 1-7, characterized in that: the seaweed jade kettle soup comprises the following components in parts by weight:
25-35 parts of seaweed, 25-35 parts of kelp, 10-20 parts of fritillaria, 10-20 parts of pinellia ternate, 15-25 parts of green tangerine peel, 15-25 parts of dried orange peel, 20-25 parts of Chinese angelica, 20-25 parts of ligusticum wallichii, 10-20 parts of fructus forsythiae, 5-15 parts of radix angelicae pubescentis and 4-8 parts of liquorice;
further preferably, the seaweed jade kettle soup is composed of the following components in parts by weight:
25 parts of seaweed, 25 parts of kelp, 15 parts of fritillaria, 15 parts of pinellia ternate, 20 parts of green tangerine peel, 20 parts of dried orange peel, 20 parts of Chinese angelica, 20 parts of ligusticum wallichii, 15 parts of fructus forsythiae, 15 parts of radix angelicae pubescentis and 6 parts of liquorice.
9. The use according to claim 8, characterized in that: the seaweed Yu Hu Tang is an oral preparation prepared by adding pharmaceutically acceptable auxiliary materials or auxiliary components on the basis of the raw materials;
wherein at least any one of the following is satisfied:
preferably, the oral preparation comprises a solid preparation, a liquid preparation or a suspension preparation;
further preferably, the solid preparation comprises capsules, tablets, pills, powder or granules;
or further preferably, the liquid formulation comprises an emulsion, a solution, a suspension, a syrup or a tincture.
10. The use according to claim 8, characterized in that: the preparation method of the seaweed jade kettle soup at least meets any one of the following conditions:
(1) The preparation method comprises the following steps:
A. weighing the following raw materials in parts by weight: 25-35 parts of seaweed, 25-35 parts of kelp, 10-20 parts of fritillaria, 10-20 parts of pinellia ternate, 15-25 parts of green tangerine peel, 15-25 parts of dried orange peel, 20-25 parts of Chinese angelica, 20-25 parts of ligusticum wallichii, 10-20 parts of fructus forsythiae, 5-15 parts of radix angelicae pubescentis and 4-8 parts of liquorice;
B. soaking in water, and decocting under the following conditions: adding water 4-6 times, decocting for 1-2 times, each for 20-40 min, and collecting decoction;
(2) Preferably, the step A is characterized in that the raw material medicines are weighed according to the following components in parts by weight: 25 parts of seaweed, 25 parts of kelp, 15 parts of fritillaria, 15 parts of pinellia ternate, 20 parts of green tangerine peel, 20 parts of dried orange peel, 20 parts of Chinese angelica, 20 parts of szechuan lovage rhizome, 15 parts of weeping forsythiae capsule, 15 parts of radix angelicae pubescentis and 6 parts of liquorice;
(3) Preferably, in the step B, the decoction is carried out for 5-15 minutes by strong fire and then 15-25 minutes by slow fire;
(4) More preferably, the decoction is carried out by decocting with strong fire for 10 minutes and then decocting with slow fire for 20 minutes;
(5) Preferably, the decocting conditions in step B are: adding water 5 times, decocting for 1 time and 30 minutes each time, and collecting decoction;
(6) Preferably, the soaking time in the step B is 5-15 minutes;
(7) Further preferably, the soaking time in step B is 10 minutes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310336514 | 2023-03-31 | ||
| CN2023103365143 | 2023-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116570676A true CN116570676A (en) | 2023-08-11 |
| CN116570676B CN116570676B (en) | 2024-08-09 |
Family
ID=87532975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310350867.9A Active CN116570676B (en) | 2023-03-31 | 2023-04-04 | Application of seaweed Yu Hu Tang in preparing medicament for treating or relieving silicosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116570676B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103800643A (en) * | 2012-11-12 | 2014-05-21 | 于延法 | Traditional Chinese medicine formula for treating goiter |
| CN108721485A (en) * | 2017-04-25 | 2018-11-02 | 郝纪涛 | It is a kind of to treat the solidifying Chinese medicine preparation of hepatosplenic disorder stagnation of the circulation of vital energy phlegm |
-
2023
- 2023-04-04 CN CN202310350867.9A patent/CN116570676B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103800643A (en) * | 2012-11-12 | 2014-05-21 | 于延法 | Traditional Chinese medicine formula for treating goiter |
| CN108721485A (en) * | 2017-04-25 | 2018-11-02 | 郝纪涛 | It is a kind of to treat the solidifying Chinese medicine preparation of hepatosplenic disorder stagnation of the circulation of vital energy phlegm |
Non-Patent Citations (6)
| Title |
|---|
| 张晓苗;裴晓华;肖金禾;刘宇飞;: "海藻玉壶汤的临床研究进展", 世界中西医结合杂志, vol. 12, no. 01, 28 January 2017 (2017-01-28), pages 145 - 148 * |
| 戴明文: "海藻玉壶汤治瘤", 四川中医, no. 07, 15 July 1988 (1988-07-15), pages 40 * |
| 晏建立: "辨证分型治疗矽肺104例疗效观察", 河南中医, vol. 14, no. 01, 20 February 1994 (1994-02-20), pages 25 - 26 * |
| 李唯佳, 余丹凤, 葛星: "海藻玉壶汤治疗瘿瘤举隅", 浙江中医杂志, no. 05, 30 May 1999 (1999-05-30), pages 203 * |
| 王业生;杜钢军;孙玲;张亚平;孙婷;宋永平;: "海藻玉壶汤对小鼠胸腺淋巴瘤生长抑制的机制研究", 中国实验方剂学杂志, vol. 19, no. 02, 7 November 2012 (2012-11-07), pages 191 - 195 * |
| 董桂湖: "尘肺病的辨证施治", 江西中医药, no. 2, 31 December 1996 (1996-12-31), pages 63 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116570676B (en) | 2024-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN105233231A (en) | Pharmaceutical composition for treating respiratory diseases | |
| CN104042767B (en) | A kind of pharmaceutical composition for the treatment of chronic pharyngitis and its production and use | |
| CN116570676B (en) | Application of seaweed Yu Hu Tang in preparing medicament for treating or relieving silicosis | |
| CN1169561C (en) | Medicine for treating diseases of rectum and anus | |
| CN112494598B (en) | Effective part composition for treating pharyngitis and application thereof | |
| CN105664063A (en) | Traditional Chinese medicine compound for improving thyroid carcinoma postoperative symptoms (syndrome of Qi stagnation and blood stasis) | |
| CN112569310B (en) | Yin-nourishing and oral liquid for treating radioactive xerostomia | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN101693077B (en) | Medicament for treating febrile bronchial asthma and chronic bronchitis | |
| CN104623152A (en) | Traditional Chinese medicine composition for treating thyroid adenoma due to phlegm-damp stagnation and preparation method thereof | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN115624602B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method and pharmaceutical application thereof | |
| JP7462783B2 (en) | Medical Use of Anemoside B4 in the Treatment of Oral Ulcers | |
| RU2803967C1 (en) | Medical use of anemozide b4 in treatment of ulcers in oral cavity | |
| CN109331154B (en) | Gel preparation for preventing postpartum uterus involution badness and use method | |
| CN109966428B (en) | Formula of nasopharynx traditional Chinese medicine flushing fluid | |
| CN109395026B (en) | Preparation method of gel preparation for preventing postpartum uterus involution badness | |
| CN109432198B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1742960A (en) | Chuanluotong Chinese medicine preparation and preparing method thereof | |
| CN105560474A (en) | Five-component traditional Chinese medicine pills for treating chronic bronchitis | |
| CN108721274B (en) | Application of arctigenin in preparation of medicine for treating chronic atrophic gastritis | |
| CN105055829A (en) | Medicine used for treating chronic laryngitis | |
| CN105770448A (en) | Medicine composition for preventing and treating perianal diseases and preparation method thereof | |
| CN105687684A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |